share_log

Exicure | 10-Q/A: Quarterly report (Amendment)

Exicure | 10-Q/A: Quarterly report (Amendment)

Exicure | 10-Q/A:季度报表(修正版)
美股sec公告 ·  05/17 04:47
牛牛AI助手已提取核心信息
Exicure, a biotechnology company, reported a challenging financial performance in its latest quarterly report. The company's revenue plummeted to $0 for the quarter ended June 30, 2023, a 100% decrease from the $2.5 million reported in the same period in 2022. Operating expenses decreased by 43% to $5.6 million, down from $9.9 million, primarily due to the suspension of research and development activities. Consequently, the operating loss improved by 25% to $5.6 million, compared to a loss of $7.5 million in the previous year. The net loss also saw a reduction of 23% year-on-year, standing at $5.8 million. Exicure's cash position weakened, with cash, cash equivalents, and restricted cash totaling $3.5 million as of June 30, 2023, down from $9.8 million at the end of 2022. The company raised $5.4 million in gross proceeds from a...Show More
Exicure, a biotechnology company, reported a challenging financial performance in its latest quarterly report. The company's revenue plummeted to $0 for the quarter ended June 30, 2023, a 100% decrease from the $2.5 million reported in the same period in 2022. Operating expenses decreased by 43% to $5.6 million, down from $9.9 million, primarily due to the suspension of research and development activities. Consequently, the operating loss improved by 25% to $5.6 million, compared to a loss of $7.5 million in the previous year. The net loss also saw a reduction of 23% year-on-year, standing at $5.8 million. Exicure's cash position weakened, with cash, cash equivalents, and restricted cash totaling $3.5 million as of June 30, 2023, down from $9.8 million at the end of 2022. The company raised $5.4 million in gross proceeds from a private placement in February 2023, but acknowledged that its current liquidity is insufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern. Exicure has ceased all research and development activities and is exploring strategic alternatives, including potential transactions in industries unrelated to its historical operations. The company is also considering equity offerings as a means to secure financing, but faces challenges due to its current condition and market uncertainties. Exicure has experienced several Nasdaq listing deficiencies, including stock price and corporate governance requirements, and is working to regain compliance to avoid delisting. The company's future plans are focused on exploring strategic alternatives and securing the necessary financing to continue operations, with the possibility of bankruptcy protection if additional capital cannot be raised.
生物技术公司Exicure在其最新的季度报告中报告了艰难的财务业绩。截至2023年6月30日的季度,该公司的收入暴跌至0美元,较2022年同期公布的250万美元下降了100%。运营支出从990万美元下降了43%至560万美元,这主要是由于研发活动的暂停。因此,与去年的亏损750万美元相比,营业亏损增加了25%,达到560万美元。净亏损也同比下降了23%,为580万美元。Exicure的现金状况疲软,截至2023年6月30日,现金、现金等价物和限制性现金总额为350万美元,低于2022年底的980万美元。该公司在2023年2月通过私募募筹集了540万澳元的总收益,但承认其目前的流动性不足以为未来...展开全部
生物技术公司Exicure在其最新的季度报告中报告了艰难的财务业绩。截至2023年6月30日的季度,该公司的收入暴跌至0美元,较2022年同期公布的250万美元下降了100%。运营支出从990万美元下降了43%至560万美元,这主要是由于研发活动的暂停。因此,与去年的亏损750万美元相比,营业亏损增加了25%,达到560万美元。净亏损也同比下降了23%,为580万美元。Exicure的现金状况疲软,截至2023年6月30日,现金、现金等价物和限制性现金总额为350万美元,低于2022年底的980万美元。该公司在2023年2月通过私募募筹集了540万澳元的总收益,但承认其目前的流动性不足以为未来十二个月的运营提供资金,这引发了人们对其继续经营能力的严重怀疑。Exicure已停止所有研发活动,正在探索战略替代方案,包括与其历史业务无关的行业的潜在交易。该公司也在考虑将股票发行作为确保融资的一种手段,但由于其当前状况和市场不确定性而面临挑战。Exicure遇到了一些纳斯达克上市缺陷,包括股价和公司治理要求,并正在努力恢复合规以避免退市。该公司的未来计划侧重于探索战略替代方案和确保必要的融资以继续运营,如果无法筹集额外资金,则有可能获得破产保护。

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成,只对中国内地以外的地区提供。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。